Viking Therapeutics, Inc.
Clinical trials sponsored by Viking Therapeutics, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing metabolic and endocrine therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New weekly shot could help diabetics shed pounds
Disease control OngoingThis phase 3 trial is testing a weekly injection called VK2735 to help people with type 2 diabetes who are overweight or obese lose weight. About 1,100 participants will receive either the drug or a placebo for 78 weeks. The study measures how much weight they lose and whether th…
Phase: PHASE3 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New obesity drug VK2735 enters final testing phase
Disease control OngoingThis study tests an experimental drug called VK2735, given as a weekly injection, to help people with obesity or overweight lose weight. About 4500 adults without diabetes will receive either the drug or a placebo for 78 weeks. The main goal is to see how much weight they lose an…
Phase: PHASE3 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC